Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma

吉西他滨 医学 内科学 养生 化疗 白细胞减少症 肿瘤科 不利影响 紫杉醇 胃肠病学
作者
Zhou Zhu,Hui Tang,Jinrong Ying,Yuejuan Cheng,Xiang Wang,Yingyi Wang,Chunmei Bai
出处
期刊:Cancer biology and medicine [Chinese Anti-Cancer Association]
卷期号:20 (10): 1-14 被引量:6
标识
DOI:10.20892/j.issn.2095-3941.2023.0189
摘要

Objective: Gemcitabine plus nab-paclitaxel (GnP) is the standard first-line therapy for advanced pancreatic ductal adenocarcinoma (PDAC). S-1, an oral fluoropyrimidine derivative, as compared with gemcitabine, is non-inferior in terms of overall survival (OS) and is associated with lower hematologic toxicity. Accordingly, S-1 is a convenient oral alternative treatment for advanced PDAC. This study was aimed at comparing the efficacy and safety of gemcitabine plus S-1 (GS) vs. GnP as first-line chemotherapy for advanced PDAC. Methods: Patients with advanced PDAC who received first-line GS or GnP at the Peking Union Medical College Hospital between March 2011 and November 2022 were evaluated. Results: A total of 300 patients were assessed, of whom 84 received GS and 216 received GnP. The chemotherapy completion rate was higher with GS than GnP (50.0% vs. 30.3%, P = 0.0028). The objective response rate (ORR) was slightly higher (14.3% vs. 9.7%, P = 0.35), and the median OS was significantly longer (17.9 months vs. 13.3 months, P = 0.0078), in the GS group than the GnP group. However, the median progression-free survival (PFS) did not significantly differ between groups. Leukopenia risk was significantly lower in the GS group than the GnP group (14.9% vs. 28.1%, P = 0.049). Conclusions: As first-line chemotherapy for advanced PDAC, the GS regimen led to a significantly longer OS than the GnP regimen. The PFS, ORR, and incidence of severe adverse events were comparable between the GS and GnP groups.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
我是老大的应助被尘南浔采纳,获得10
刚刚
热心万天发布了新的文献求助10
刚刚
1秒前
1秒前
打打的应助被拓跋涵易采纳,获得10
1秒前
有病早治完成签到 ,获得积分10
2秒前
汉堡包的应助被liyu采纳,获得10
2秒前
freshme完成签到,获得积分10
3秒前
科研通AI6.2的应助被叶林海采纳,获得10
3秒前
3秒前
青衣完成签到,获得积分10
4秒前
Ava的应助被shenxian82133采纳,获得10
5秒前
wyy发布了新的文献求助10
5秒前
强强发布了新的文献求助10
5秒前
111发布了新的文献求助10
6秒前
昔年完成签到 ,获得积分10
7秒前
Owen的应助被LUXURY采纳,获得10
7秒前
阿阿阿Q完成签到,获得积分10
8秒前
8秒前
充电宝的应助被zhikaiyici采纳,获得30
8秒前
9秒前
缓慢的秋莲完成签到,获得积分10
9秒前
YD发布了新的文献求助10
9秒前
11秒前
gwf971021完成签到,获得积分10
11秒前
sskaze完成签到,获得积分10
11秒前
12秒前
科目三的应助被fyj采纳,获得10
12秒前
上官老黑完成签到 ,获得积分10
13秒前
ovo完成签到 ,获得积分10
13秒前
周一发布了新的文献求助10
14秒前
paper_king发布了新的文献求助10
14秒前
14秒前
15秒前
Alex完成签到,获得积分10
15秒前
开心的老虎完成签到 ,获得积分10
16秒前
尘南浔发布了新的文献求助10
16秒前
nwdrbb完成签到,获得积分10
18秒前
慢慢的地理人完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193653
求助须知:如何正确求助?哪些是违规求助? 9579816
关于积分的说明 21867585
捐赠科研通 7793288
什么是DOI,文献DOI怎么找? 3437343
关于科研通互助平台的介绍 2560779
邀请新用户注册赠送积分活动 2484193